Results of the INTENSITY study ,being a comparison of Onbrez Breezhaler (indacaterol) from Novartis with Spiriva(tiotropium)from Boehringer/Pfizer were announced in...
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with Chronic Obstructive Pulmonary Disease (COPD), which...
New results from a pooled post-hoc sub-group analysis from three studies (INVOLVE, INHANCE and INLIGHT2) showed that Onbrez Breezhaler/Arcapta Neohaler...
Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
The GLOW 1 and GLOW 3 studies show that investigational NVA237 (glycopyrronium bromide)from Novartis significantly increased patients' lung function compared...
Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for...
The GLOW 3 study investigated the effects of Seebri Breezhaler (NVA237), (glycopyrronium bromide) 50 mcg once-daily from Novartis on exercise...
Novartis announced that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg...
Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...
Novartis has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...